AIM ImmunoTech Announces Publication of Journal Article On the Positive Effect of Ampligen and Interferon-Alpha on Tumor Growth

Core Insights - AIM ImmunoTech Inc. announced the publication of a peer-reviewed article in the Journal for ImmunoTherapy of Cancer, demonstrating a positive combination effect of its drug Ampligen and interferon-alpha on tumor growth and subject survival [1][3] Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company focused on developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19. Its lead product, Ampligen (rintatolimod), is a first-in-class investigational drug that acts as a dsRNA and highly selective TLR3 agonist immuno-modulator [4]